Edition:
United States

Sangamo Therapeutics Inc (SGMO.OQ)

SGMO.OQ on NASDAQ Stock Exchange Global Select Market

9.50USD
21 Jul 2017
Change (% chg)

$-0.05 (-0.52%)
Prev Close
$9.55
Open
$9.60
Day's High
$9.68
Day's Low
$9.35
Volume
191,644
Avg. Vol
243,718
52-wk High
$10.50
52-wk Low
$2.65

Latest Key Developments (Source: Significant Developments)

Sangamo receives fast track status from the FDA for SB-318 and SB-913
Thursday, 13 Jul 2017 04:01pm EDT 

July 13 (Reuters) - Sangamo Therapeutics Inc :Sangamo receives fast track designation from the FDA for SB-318 and SB-913 in vivo genome editing product candidates for the treatment of MPS I and MPS II.  Full Article

Sangamo announces pricing of $72.5 mln public offering of common stock
Wednesday, 21 Jun 2017 08:26am EDT 

June 21 (Reuters) - Sangamo Therapeutics Inc :Sangamo therapeutics announces pricing of $72.5 million public offering of common stock.Sangamo therapeutics announces pricing of $72.5 million public offering of common stock.Says public offering of 10.0 million common shares priced at $7.25per share.  Full Article

Sangamo Therapeutics announces proposed public offering of common stock
Tuesday, 20 Jun 2017 04:01pm EDT 

June 20 (Reuters) - Sangamo Therapeutics Inc -:Sangamo Therapeutics announces proposed public offering of common stock.  Full Article

Sangamo Therapeutics updates on SB-525 investigational hemophilia A gene therapy
Wednesday, 7 Jun 2017 07:30am EDT 

June 7 (Reuters) - Sangamo Therapeutics::Sangamo Therapeutics and Pfizer announce that SB-525 investigational hemophilia A gene therapy receives orphan medicinal product designation from the European medicines agency.Cos also announce Phase 1/2 clinical trial evaluating SB-525 in adults with severe hemophilia A is now open for enrollment.Sangamo Therapeutics Inc - initial data from study of SB-525 in adults with hemophilia A expected in late 2017 or early 2018.  Full Article

Adage Capital Partners L.P. reports 5.56 pct passive stake in Sangamo Therapeutics
Friday, 2 Jun 2017 04:14pm EDT 

June 2 (Reuters) - Sangamo Therapeutics Inc : :Adage Capital Partners L.P. reports 5.56 percent passive stake in Sangamo Therapeutics Inc as of May 25, 2017 .  Full Article

Sangamo Therapeutics enters into amended and restated agreement with Cowen and Company
Friday, 26 May 2017 05:04pm EDT 

May 26 (Reuters) - Sangamo Therapeutics Inc :On May 26 co entered into amended and restated at-market offering program sales agreement with Cowen and Company.Co may issue and sell from time to time up to $75.0 million of common stock, par value $0.01 per share, through Cowen as sales agent.Amended sales agreement amends and restates in its entirety and supersedes sales agreement dated December 7, 2016.  Full Article

Sangamo receives fast track designation from FDA for SB-525
Tuesday, 16 May 2017 07:30am EDT 

May 16 (Reuters) - Pfizer Inc -:Sangamo receives fast track designation from the FDA for sb-525 investigational hemophilia a gene therapy.Sangamo Therapeutics Inc says data from phase 1/2 clinical trial evaluating sb-525 in adults with hemophilia a expected in late 2017 or early 2018.  Full Article

Sangamo Therapeutics reports Q1 revenue $3.4 million
Wednesday, 10 May 2017 04:01pm EDT 

May 10 (Reuters) - Sangamo Therapeutics Inc :Sangamo Therapeutics reports first quarter 2017 financial results.Q1 revenue $3.4 million versus I/B/E/S view $4.3 million.Q1 loss per share $0.23.Q1 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.  Full Article

Sangamo Therapeutics and Pfizer announce collaboration for Hemophilia A gene therapy
Wednesday, 10 May 2017 04:01pm EDT 

May 10 (Reuters) - Pfizer Inc :Sangamo Therapeutics and Pfizer announce collaboration for Hemophilia A gene therapy.Sangamo Therapeutics Inc says under terms of collaboration agreement, Sangamo will receive a $70 million upfront payment from Pfizer.Sangamo Therapeutics Inc says Sangamo will be responsible for conducting SB-525 phase 1/2 clinical study and certain manufacturing activities.Sangamo -Pfizer will be operationally and financially responsible for subsequent research, development, manufacturing and commercialization activities for SB-525.Sangamo Therapeutics Inc says Sangamo is eligible to receive potential milestone payments of up to $475 million.Sangamo Therapeutics Inc says Sangamo will also receive tiered double-digit royalties on net sales.Sangamo Therapeutics Inc says additionally, Sangamo will be collaborating with Pfizer on manufacturing and technical operations utilizing viral delivery vectors.  Full Article

Sangamo Therapeutics says special regulatory designations from FDA for 3 clinical programs
Thursday, 4 May 2017 08:00am EDT 

May 4 (Reuters) - Sangamo Therapeutics Inc :Sangamo therapeutics announces special regulatory designations from the fda for three clinical programs.Sangamo therapeutics inc- rare pediatric disease designation for sb-913 in vivo genome editing treatment for mps ii.Sangamo therapeutics inc- orphan drug designation for sb-525 cdna gene therapy for hemophilia a.Sangamo therapeutics inc- fast track designation for sb-fix in vivo genome editing treatment for hemophilia b.  Full Article

BRIEF-Sangamo Therapeutics appoints Roger Jeffs, Joseph Zakrzewski to its board

* Sangamo Therapeutics appoints Roger Jeffs, PH.D. and Joseph S. Zakrzewski to its board of directors